<DOC>
	<DOCNO>NCT00356161</DOCNO>
	<brief_summary>Procedures provide interventional implantation port catheter system hepatic artery adjacent regional chemotherapy liver optimize scope open , single-arm trial patient metastases cancer confine liver . The primary objective improvement indication , implantation procedure , regional chemotherapy . Secondary objective port patency , comparison complication historical collective patient provide surgical hepatic arterial port device ( colorectal cancer patient ) , progression free overall survival , efficacy maintain regional chemotherapy 5-FU combination systemic treatment patient extrahepatic progression , quality life .</brief_summary>
	<brief_title>HAI Via Interventionally Implanted Port Catheter Systems</brief_title>
	<detailed_description>Inclusion criterion : - histologically confirm hepatic cancer without symptomatic extrahepatic manifestation . - non-resectable disease hepatic resection ablation past 8 week . - measurable disease ( least hepatic resection ) - Karnofsky performance status = &gt; 70 % , ECOG status 0-2 - &gt; 18 year age - life expectancy &gt; 6 month - compliance patient - write informed consent Exclusion criterion : - second neoplasia within past 3 year , except non-melanotic skin cancer , adequately treat Ca situ cervix uterus , adequately resected second colorectal cancer ( patient liver metastasis colorectal cancer ) - symptomatic extrahepatic disease , particular disseminate bone metastasis , brain metastasis - liver cirrhosis portal hypertension , active hepatitis B C , previous percutaneous radiotherapy liver - active infection - history gastric duodenal ulcer - symptomatic uncontrolled peripheral arterial occlusive disease , history stenosis renal artery . - history dilatative cardiomyopathy , vitium mitral aortic valve , persist foramen ovale , atrial fibrillation - artificial heart valve vascular - history diabetic microangiopathy - uncontrolled hyperthyriodism - severe concomitant disease ( heart failure &gt; NYHA 2Â° , respiratory failure , renal failure &gt; stage2 , liver failure ( TPZ &lt; 50 % ) . - inherit acquired immunodeficiency syndrome - contraindication 5-FU - pregnancy nursing , contraception - limited contractual capability . After enrollment , port catheter catheter system interventionally implant hepatic artery patient schedule regional chemotherapy accord one 8 pre-defined chemotherapy schedule . All regimen base 5-fluorouracil leucovorin , optionally contain intraarterial mitomycin , oxaliplatin , additional intravenous irinotecan . Patients follow evaluated primary secondary endpoint . After inclusion 50 patient treat follow institution , study population extend 100 patient 8/2004 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>see see</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>colorectal neoplasm</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>gallbladder cancer</keyword>
	<keyword>bile duct cancer</keyword>
	<keyword>hepatic arterial infusion</keyword>
</DOC>